Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07828327
Starting soon Not applicable

Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma

NCT07828327 · tracked via the Priya Life Science China tracker
Sponsor
Qianfoshan Hospital
Phase
Not applicable
Started
2026-11-01
Last updated
2026-09-24

Condition(s) studied

Allergic Bronchopulmonary AspergillosisABPASevere Eosinophilic Asthma

Investigational drug(s) / intervention(s)

Depemokimab →

Depemokimab: 100 mg (1mL) Subcutaneous Solution

Study summary

An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Female and Male patients aged 18-75 years * Diagnosis of Allergic Bronchopulmonary Aspergillosis (according to the ISHAM Working Group Diagnostic Criteria) * Severe asthma requiring treatment with high dose ICS plus a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), or maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control) Exclusion Criteria: * History of allergy or hypersensitivity reaction to Depemokimab or any of its components. * Currently pregnant, breastfeeding, or lactating women. * Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational.

Primary outcome measure(s)

  • Number of steroid requiring exacerbations — 26 weeks
    Number of asthma exacerbations requiring the initiation of (or temporary increase in) systemic corticosteroids in severe eosinophilic asthma complicated by ABPA

Trial sites (1)

FacilityCityRegionStatus
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China Jinan Shandong

More Qianfoshan Hospital trials in China

Study on Topping-off Technique for Treating LDD Recruiting
TAS-102 Plus Radiotherapy in Elderly ESCC Starting soon
Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin Recruiting
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis Recruiting
Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury Active, not recruiting

Other trials for the same condition

Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis Recruiting
Fungal Status and Prognosis in ABPA Recruiting
ML-Based ABPA Recurrence Prediction and Clinical Utility Recruiting
A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA Recruiting
A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07828327 on ClinicalTrials.gov ↗ ← All trials in China